A conceptual breakdown exploring whether removing recursion improves reinforcement learning models, focusing on stability, ...

With an IPO raise of $625 million, Kailera Therapeutics now holds the new record for the largest public market debut.

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is among the best medical AI stocks to buy now. On March 31, Recursion moved to ...

Recursion Pharmaceuticals expanded its collaboration with Citeline to integrate real world data into its AI enabled ClinTech Platform. The partnership is aimed at refining clinical trial design and ...

Recursion Pharmaceuticals, Inc. (RXRX) 25th Annual Needham Virtual Healthcare Conference April 13, 2026 12:45 PM EDTCompany ParticipantsBen Taylor - ...

Recursion Pharmaceuticals executives discussed the company’s artificial intelligence-driven drug discovery platform during a ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cardiff Oncology , Revolution Medicines and Legend Biotech with bullish sentiments ...

Citeline, a leader in clinical solutions for the life sciences industry, today announced an expanded strategic partnership with Recursion (NASDAQ: RXRX), a leading tech-bio company decoding biology ...

View Recursion Pharmaceuticals, Inc. Class A RXRX stock quote prices, financial information, real-time forecasts, and company news from CNN.

Some seemingly simple sequences of multiplication and addition grow so quickly that they question the very foundations of ...

As Project Hail Mary grips audiences with its mix of science and survival, these five gripping novels offer more journeys ...

In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $3.60, marking a -4% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.26%.